title: The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats.
abstract: Immunosuppressants have been associated with increased cardiovascular disease risk. We determined the effects of calcineurin and mammalian target of rapamycin (mTOR) inhibitor administration on endothelial dysfunction and associated inflammation and oxidative stress in adult rats. Cyclosporine A (low and high dose), sirolimus, tacrolimus, everolimus and placebo were administered to 8-week-old male Wistar rats for 10 consecutive days. Aortic vascular endothelial and smooth muscle function were assessed ex vivo in organ baths. Maximal aortic contraction to noradrenaline in sirolimus-treated rats was significantly greater than cyclosporine groups, everolimus and placebo, whereas endothelial-dependent relaxation was significantly impaired with cyclosporine and tacrolimus compared with everolimus. Endothelial-independent relaxation was impaired in tacrolimus-treated rats compared with low dose cyclosporine, everolimus and sirolimus. Sirolimus was associated with a reduction in plasma interleukin (IL)-1β and tumour necrosis factor (TNF)-α and higher levels of catalase and total antioxidant status. In nontransplanted rats, vascular dysfunction was evident following administration of cyclosporine A, sirolimus and tacrolimus, whereas everolimus did not compromise aortic endothelial or smooth muscle function. At the doses administered in this model, the immunosuppressants exerted varying effects on vascular function.
authors.affiliation: School of Human Life Sciences, University of Tasmania, Launceston, Australia. cecilia.shing@utas.edu.au
authors.forename: Cecilia M
authors.initials: CM
authors.lastname: Shing
authors.forename: Robert G
authors.initials: RG
authors.lastname: Fassett
authors.forename: Lindsay
authors.initials: L
authors.lastname: Brown
authors.forename: Jeff S
authors.initials: JS
authors.lastname: Coombes
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects*; D015415:Biomarkers / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D016207:Cytokines / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects*; D000068338:Everolimus; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007249:Inflammation / Q000097:blood / Q000139:chemically induced*; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects*; D018384:Oxidative Stress; D051381:Rats; D017208:Rats, Wistar; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D015415:Biomarkers; D016207:Cytokines; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D020123:Sirolimus; D016559:Tacrolimus